Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 110

Sort by

Sort Order Select

Journal Articles

Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Blood (2024) 144 (14): 1486–1495.

https://doi.org/10.1182/blood.2023023780

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular and clinical presentation of UBA1 -mutated myelodysplastic syndromes

Maria Sirenko, Elsa Bernard, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E. Arango Ossa, Olivier Kosmider, Robert Hasserjian, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Carmelo Gurnari, Matilde Yung Follo, Felicitas Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Birgitta Sander, Elisa Orna, Katharina Zoldan, Lea Naomi Eder, Wolfgang R. Sperr, Renate Thalhammer, Christina Ganster, Lionel Adès, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio P. S. Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B. Beck, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2024) 144 (11): 1221–1229.

https://doi.org/10.1182/blood.2023023723

Published: 2024

Includes: Supplemental data

Journal Articles

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Blood (2024) 143 (11): 1006–1017.

https://doi.org/10.1182/blood.2023020515

Published: 2024

Includes: Supplemental data

Journal Articles

Inactivation of DNA Polymerase Theta (PolΘ) Is Synthetic Lethal in DNMT3A Mutated Myeloid Malignancies - Potential Clinical Applications

Bac Viet Le, Umeshkumar Vekariya, Monika Toma, Margaret Nieborowska-Skorska, Marie-Christine Caron, George Vassiliou, Malgorzata Gozdecka, Zayd Haydar, Gurushankar Chandramouly, Emir Hadzijusufovic, Wolfgang R. Sperr, Richard Pomerantz, Peter Valent, Jean-Yves Masson, Gaorav Gupta, Grant A Challen, Tomasz Skorski

Blood (2023) 142 (Supplement 1): 580.

https://doi.org/10.1182/blood-2023-174333

Published: 2023

Journal Articles

Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies

Irene Graf, Georg Greiner, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knöbl, Alexander Hauswirth, Manja Meggendorfer, Ulrich Jaeger, Constance Baer, Torsten Haferlach, Gregor Hoermann, Peter Valent, Wolfgang R. Sperr

Blood (2022) 140 (Supplement 1): 11634–11635.

https://doi.org/10.1182/blood-2022-162588

Published: 2022

Journal Articles

A STAT5B–CD9 axis determines self-renewal in hematopoietic and leukemic stem cells

Sebastian Kollmann, Reinhard Grausenburger, Thorsten Klampfl, Michaela Prchal-Murphy, Klavdija Bastl, Hanja Pisa, Vanessa M. Knab, Tania Brandstoetter, Eszter Doma, Wolfgang R. Sperr, Sabine Lagger, Matthias Farlik, Richard Moriggl, Peter Valent, Florian Halbritter, Karoline Kollmann, Gerwin Heller, Barbara Maurer, Veronika Sexl

Blood (2021) 138 (23): 2347–2359.

https://doi.org/10.1182/blood.2021010980

Published: 2021

Includes: Supplemental data

Journal Articles

NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML

Irene Graf, Georg Greiner, Rodrig Marculescu, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knoebl, Ulrich Jaeger, Alexander Hauswirth, Ilse Schwarzinger, Renate Thalhammer, Michael Kundi, Gregor Hoermann, Gerlinde Mitterbauer-Hohendanner, Peter Valent, Wolfgang R. Sperr

Blood (2021) 138 (Supplement 1): 3435.

https://doi.org/10.1182/blood-2021-149526

Published: 2021

Journal Articles

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Blood (2021) 138 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2021-145401

Published: 2021

Journal Articles

Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance

Yueksel Filik, Karin Bauer, Barbara Peter, Emir Hadzijusufovic, Georg Greiner, Nadine Witzeneder, Gregor Hoermann, Karoline V. Gleixner, Wolfgang R. Sperr, Peter Valent

Blood (2021) 138 (Supplement 1): 1481.

https://doi.org/10.1182/blood-2021-152415

Published: 2021

Journal Articles

Emicizumab for the treatment of acquired hemophilia A

Paul Knoebl, Johannes Thaler, Petra Jilma, Peter Quehenberger, Karoline Gleixner, Wolfgang R. Sperr

Blood (2021) 137 (3): 410–419.

https://doi.org/10.1182/blood.2020006315

Published: 2021

Includes: Supplemental data

Journal Articles

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Blood (2021) 137 (2): 238–247.

https://doi.org/10.1182/blood.2020006157

Published: 2021

Includes: Supplemental data

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

Phenotyping of Disease-Initiating CD34 + /CD38 ─ Stem Cells in BCR-ABL1 ─ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens

Blood (2020) 136 (Supplement 1): 53.

https://doi.org/10.1182/blood-2020-140477

Published: 2020

Journal Articles

Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-140776

Published: 2020

Journal Articles

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Mathias A. Schneeweiss, Greiner Georg, MD PhD, Susanne Herndlhofer, Julia Schellnegger, Maria-Theresa Krauth, MD, Friedrich Wimazal, MD, Corinna Steinhauser, Renate Thalhammer, MD, Ilse Schwarzinger, MD, Harald Esterbauer, MD PhD, Manuela Födinger, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2019) 134 (Supplement_1): 4269.

https://doi.org/10.1182/blood-2019-123390

Published: 2019

Journal Articles

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)

Gregor Eisenwort, MD PhD, Alexandra Keller, Michael Willmann, Irina Sadovnik, Greiner Georg, MD PhD, Karoline V. Gleixner, MD, Daniel Ivanov, MSc, Daniela Berger, Gabriele Stefanzl, Christiana Winding, DVM, Gregor Hoermann, Wolfgang R. Sperr, MD, Heinz Sill, MD, Peter Bettelheim, MD, Klaus Geissler, MD, Michael W. Deininger, Thomas Rülicke, Peter Valent, MD

Blood (2019) 134 (Supplement_1): 4223.

https://doi.org/10.1182/blood-2019-122530

Published: 2019

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

Journal Articles

The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q

Blood (2018) 132 (Supplement 1): 4360.

https://doi.org/10.1182/blood-2018-99-114026

Published: 2018

Journal Articles

KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

Blood (2018) 132 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2018-99-115895

Published: 2018

Journal Articles

BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph + CML

Barbara Peter, Gregor Eisenwort, Alexandra Keller, Karin Bauer, Daniela Berger, Irina Sadovnik, Gabriele Stefanzl, Gregor Hoermann, Dominik Wolf, Zdenek Racil, Jiří Mayer, Johannes Zuber, Wolfgang R. Sperr, Georg E. Winter, Michael Willmann, Thomas Rülicke, Peter Valent

Blood (2018) 132 (Supplement 1): 1722.

https://doi.org/10.1182/blood-2018-99-111126

Published: 2018

NARROW

Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Molecular and clinical presentation of UBA1 -mutated myelodysplastic syndromes

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Inactivation of DNA Polymerase Theta (PolΘ) Is Synthetic Lethal in DNMT3A Mutated Myeloid Malignancies - Potential Clinical Applications

Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies

A STAT5B–CD9 axis determines self-renewal in hematopoietic and leukemic stem cells

NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance

Emicizumab for the treatment of acquired hemophilia A

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Phenotyping of Disease-Initiating CD34 + /CD38 ─ Stem Cells in BCR-ABL1 ─ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens

Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q

KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph + CML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only